Leerink Partnrs Issues Pessimistic Outlook for RAPT Earnings

Rapt Therapeutics (NASDAQ:RAPT) – Equities researchers at Leerink Partnrs decreased their FY2026 EPS estimates for shares of Rapt Therapeutics in a research report issued to clients and investors on Monday, October 20th. Leerink Partnrs analyst T. Smith now anticipates that the company will earn ($3.45) per share for the year, down from their prior estimate of ($3.25). Leerink Partnrs has a “Strong-Buy” rating on the stock. The consensus estimate for Rapt Therapeutics’ current full-year earnings is ($2.14) per share. Leerink Partnrs also issued estimates for Rapt Therapeutics’ FY2027 earnings at ($4.78) EPS, FY2028 earnings at ($4.89) EPS and FY2029 earnings at ($7.77) EPS.

Rapt Therapeutics (NASDAQ:RAPT) last released its quarterly earnings data on Thursday, August 7th. The company reported ($0.65) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.61) by ($0.04).

RAPT has been the subject of a number of other research reports. HC Wainwright raised their price target on Rapt Therapeutics to $27.00 and gave the company a “buy” rating in a research report on Thursday, July 10th. Weiss Ratings restated a “sell (d-)” rating on shares of Rapt Therapeutics in a research report on Wednesday, October 8th. Zacks Research cut Rapt Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Friday, August 22nd. JPMorgan Chase & Co. upgraded Rapt Therapeutics from a “neutral” rating to an “overweight” rating and raised their price target for the company from $13.00 to $55.00 in a research report on Monday. Finally, Wells Fargo & Company restated an “overweight” rating and issued a $48.00 price target (up previously from $38.00) on shares of Rapt Therapeutics in a research report on Tuesday. Two research analysts have rated the stock with a Strong Buy rating, five have issued a Buy rating, four have given a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Rapt Therapeutics presently has an average rating of “Moderate Buy” and an average price target of $33.00.

Rapt Therapeutics Stock Performance

NASDAQ:RAPT opened at $30.00 on Thursday. The stock has a fifty day moving average price of $19.90 and a two-hundred day moving average price of $12.40. The stock has a market capitalization of $496.20 million, a price-to-earnings ratio of -2.12 and a beta of 0.23. Rapt Therapeutics has a 1 year low of $5.67 and a 1 year high of $42.39.

Institutional Trading of Rapt Therapeutics

A number of large investors have recently made changes to their positions in RAPT. Charles Schwab Investment Management Inc. boosted its stake in shares of Rapt Therapeutics by 112.7% during the first quarter. Charles Schwab Investment Management Inc. now owns 150,946 shares of the company’s stock valued at $184,000 after acquiring an additional 79,967 shares during the last quarter. Invesco Ltd. boosted its stake in shares of Rapt Therapeutics by 411.7% during the first quarter. Invesco Ltd. now owns 58,901 shares of the company’s stock valued at $72,000 after acquiring an additional 47,391 shares during the last quarter. Nuveen LLC acquired a new stake in shares of Rapt Therapeutics during the first quarter valued at $143,000. Callan Family Office LLC boosted its stake in Rapt Therapeutics by 53.9% in the 1st quarter. Callan Family Office LLC now owns 89,327 shares of the company’s stock worth $109,000 after buying an additional 31,287 shares during the last quarter. Finally, Comerica Bank boosted its stake in Rapt Therapeutics by 53.9% in the 1st quarter. Comerica Bank now owns 89,327 shares of the company’s stock worth $109,000 after buying an additional 31,287 shares during the last quarter. Institutional investors and hedge funds own 99.09% of the company’s stock.

Rapt Therapeutics Company Profile

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.